Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Other Non-Current Assets (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Other Non-Current Assets readings, the most recent being $13.7 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 0.72% to $13.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.7 million, a 0.72% increase, with the full-year FY2025 number at $13.7 million, up 0.72% from a year prior.
  • Other Non-Current Assets hit $13.7 million in Q4 2025 for Amicus Therapeutics, up from $12.9 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $25.2 million in Q1 2022 to a low of $12.9 million in Q3 2025.
  • Median Other Non-Current Assets over the past 5 years was $18.6 million (2023), compared with a mean of $18.4 million.
  • Biggest five-year swings in Other Non-Current Assets: increased 27.92% in 2021 and later plummeted 30.95% in 2025.
  • Amicus Therapeutics' Other Non-Current Assets stood at $24.4 million in 2021, then fell by 21.23% to $19.2 million in 2022, then fell by 3.58% to $18.6 million in 2023, then decreased by 26.48% to $13.6 million in 2024, then grew by 0.72% to $13.7 million in 2025.
  • The last three reported values for Other Non-Current Assets were $13.7 million (Q4 2025), $12.9 million (Q3 2025), and $13.4 million (Q2 2025) per Business Quant data.